Pharma's Almanac TV
PA TV
Dashboard
Your Name
Your Email
Manage Account
Sign Out
Sign In
Register
Topics
Products
ADC
API - Small Molecule
Biologics
Biopharmaceuticals
Biosimilars
Cell and Gene Therapy
DNA
Drug Product
Drug Substance
Equipment
Generics
Immunotherapy
Injectables
Monoclonal Antibody
Novel Therapeutics
Oral Solid Dosage
Orphan Drugs
Parenterals
Stem Cells
Vaccine
Services
Big Data
Bioprocessing
Clinical Trials
Continuous Manufacturing
Diagnostics
Drug Delivery
Drug Development
Drug Discovery
Facility
Formulation
Innovation
Oncology
Patient Adherence
Patient Centric
Preclinical
Process Development
Quality
Regulatory
Research
Serialization
Segment
Biomanufacturing
Biotechnology
CDMO
Consulting
CRO
Engineering
Equipment
Excipients
Healthcare
Intermediates
Logistics
Manufacturing
Packaging
Supply Chain
Business
Agreement
Appointment
Business
Capacity Expansion
Collaboration
Growth
Investment
Licensing
M&A
Market Expansion
Market Intelligence
Market Prediction
New Facility
Strategic Partnership
Research
CDMO
CRO
Excipients
Pharmaceutical Equipment
Pharmaceutical Intermediates
Supply Chain Logistics
Magazine
Current Issue
Archive
Community
Company A to Z
Content Filter
More+
Staffing
Media Kit
By The Numbers
Alnylam
5 Articles Available
Can't find what you're looking for? Try our
advanced search
.
COVID-19
Vir and Alnylam Identify RNAi Therapeutic Development Candidate Targeting SARS-CoV-2
PR-M05-20-NI-008
Partnership
Regeneron Expands Partnership with RNAi Drug Developer Alnylam
PAO-M04-19-NI-013
Genetic Testing
Invitae expands work with Alnylam Pharmaceuticals to provide access to genetic testing for primary hyperoxaluria
PR-M11-18-NI-010
Distribution Agreement
Orsini Healthcare Specialty Pharmacy Selected by Alnylam Pharmaceuticals to Distribute ONPATTRO™ (patisiran)
PR-M09-18-NI-019
FDA Approval
Alnylam Announces First-Ever FDA Approval of an RNAi Therapeutic, ONPATTRO™(patisiran) for the Treatment of the Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults
PR-M09-18-NI-003
